Nexalin Technology, Inc. (NASDAQ:NXL) Short Interest Update

by · The Cerbat Gem

Nexalin Technology, Inc. (NASDAQ:NXL – Get Free Report) was the recipient of a large decrease in short interest during the month of December. As of December 15th, there was short interest totaling 50,851 shares, a decrease of 51.4% from the November 30th total of 104,655 shares. Currently, 0.4% of the company’s stock are sold short. Based on an average daily volume of 127,930 shares, the short-interest ratio is presently 0.4 days. Based on an average daily volume of 127,930 shares, the short-interest ratio is presently 0.4 days. Currently, 0.4% of the company’s stock are sold short.

Wall Street Analysts Forecast Growth

NXL has been the topic of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nexalin Technology in a research report on Monday, December 22nd. Wall Street Zen lowered Nexalin Technology from a “hold” rating to a “sell” rating in a research note on Saturday, November 22nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Nexalin Technology has an average rating of “Hold” and a consensus price target of $5.00.

Get Our Latest Stock Report on NXL

Nexalin Technology Stock Down 9.0%

Shares of NASDAQ:NXL traded down $0.06 during trading on Friday, hitting $0.63. The stock had a trading volume of 300,545 shares, compared to its average volume of 143,352. Nexalin Technology has a 12-month low of $0.61 and a 12-month high of $3.87. The stock has a market capitalization of $11.75 million, a price-to-earnings ratio of -0.95 and a beta of 3.75. The stock has a 50-day simple moving average of $1.12 and a two-hundred day simple moving average of $1.05.

Nexalin Technology (NASDAQ:NXL – Get Free Report) last issued its earnings results on Friday, November 14th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). Nexalin Technology had a negative net margin of 5,527.39% and a negative return on equity of 207.46%. The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.04 million.

Institutional Investors Weigh In On Nexalin Technology

A hedge fund recently bought a new stake in Nexalin Technology stock. Susquehanna International Group LLP acquired a new stake in Nexalin Technology, Inc. (NASDAQ:NXL – Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 62,498 shares of the company’s stock, valued at approximately $57,000. Susquehanna International Group LLP owned 0.35% of Nexalin Technology as of its most recent SEC filing. Hedge funds and other institutional investors own 0.65% of the company’s stock.

Nexalin Technology Company Profile

(Get Free Report)

Nexalin Technology, Inc is a U.S.-based medical device company specializing in noninvasive neuromodulation therapies for mental health conditions. The company develops and markets the Nexalin® medical device platform, which delivers proprietary alternating current waveforms to targeted areas of the brain through forehead-mounted electrodes. Its technology is designed to modulate neural activity without pharmaceuticals, positioning the company within the growing field of digital therapeutics and neurostimulation.

The Nexalin device has received U.S.

See Also